GuidelineAnnals of the rheumatic diseases2012
European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies.
Guideline in Annals of the rheumatic diseases, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 130 papers, 11 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
130 citing papers in PubMed, 11 syntheses or guidelines pooled it, 447 citations in OpenAlex.
- Efficacy and safety of pharmacological treatment of psoriatic arthritis: a systematic literature research informing the 2023 update of the EULAR recommendations for the management of psoriatic arthritis.Annals of the rheumatic diseases · 2024Pooled it
- EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update.Annals of the rheumatic diseases · 2020Guideline
- French guidelines on the use of systemic treatments for moderate-to-severe psoriasis in adults.Journal of the European Academy of Dermatology and Venereology : JEADV · 2019Guideline
- Standards of care and quality indicators for multidisciplinary care models for psoriatic arthritis in Spain.Rheumatology international · 2018Pooled it
- Dosing down with biologic therapies: a systematic review and clinicians' perspective.Rheumatology (Oxford, England) · 2017Pooled it
- Real-world effectiveness of anti-TNF switching in psoriatic arthritis: a systematic review of the literature.Clinical rheumatology · 2016Pooled it
- Methotrexate use and risk of lung disease in psoriasis, psoriatic arthritis, and inflammatory bowel disease: systematic literature review and meta-analysis of randomised controlled trials.BMJ (Clinical research ed.) · 2015Pooled it
- Treatment of psoriatic arthritis with anti-TNF agents: a systematic review and meta-analysis of efficacy, effectiveness and safety.Rheumatology international · 2014Pooled it
- Standards of care for patients with spondyloarthritis.Rheumatology international · 2014Guideline
- Systematic review, network meta-analysis and economic evaluation of biological therapy for the management of active psoriatic arthritis.BMC musculoskeletal disorders · 2014Pooled it
- Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force.Annals of the rheumatic diseases · 2014Pooled it
- Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial.Lancet (London, England) · 2015Trial
- Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor.Annals of the rheumatic diseases · 2014Trial
- Randomized controlled trial of a nurse-led rheumatology clinic for monitoring biological therapy.Journal of advanced nursing · 2014Trial
- A randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis.The British journal of dermatology · 2012Trial
- Switching related to inefficacy in biologics and targeted synthetic therapies for psoriatic arthritis: a comparative real-life study.Therapeutic advances in musculoskeletal disease · 2024Article
- Curative potential of Populus ciliata Wall ex. Royle extract against adjuvant-induced arthritis and peripheral neuropathy in Wistar rats.Inflammopharmacology · 2023Article
- Identifying Predictors of First-Line Subcutaneous TNF-Inhibitor Persistence in Patients with Inflammatory Arthritis: A Decision Tree Analysis by Indication.Advances in therapy · 2023Article
- Relative efficacy and safety of Janus kinase inhibitors for the treatment of active psoriatic arthritis: a network meta-analysis.Zeitschrift fur Rheumatologie · 2023Article
- Use of Methotrexate in Girls and Women of Childbearing Age, Occurrence of Methotrexate-Exposed Pregnancies and Their Outcomes in Germany: A Claims Data Analysis.Clinical drug investigation · 2023Article
70 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
36 authors at 20 institutions in 15 countries.
Funding
Abstract
backgroundPsoriatic arthritis (PsA) is a clinically heterogeneous disease. Clear consensual treatment guidance focused on the musculoskeletal manifestations of PsA would be advantageous. The authors present European League Against Rheumatism (EULAR) recommendations for the treatment of PsA with systemic or local (non-topical) symptomatic and disease-modifying antirheumatic drugs (DMARD).
methodsThe recommendations are based on evidence from systematic literature reviews performed for non-steroidal anti-inflammatory drugs (NSAID), glucocorticoids, synthetic DMARD and biological DMARD. This evidence was discussed, summarised and recommendations were formulated by a task force comprising 35 representatives, and providing levels of evidence, strength of recommendations and levels of agreement.
resultsTen recommendations were developed for treatment from NSAID through synthetic DMARD to biological agents, accounting for articular and extra-articular manifestations of PsA. Five overarching principles and a research agenda were defined.
conclusionThese recommendations are intended to provide rheumatologists, patients and other stakeholders with a consensus on the pharmacological treatment of PsA and strategies to reach optimal outcomes, based on combining evidence and expert opinion. The research agenda informs directions within EULAR and other communities interested in PsA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.